Xequel’s Proprietary aCT1 Peptide Technology Platform

Gap junctions are formed when two hemichannels from different cells align and allow for communication between the cells. In an injury, the hemichannels formed from disrupted gap junctions can result in inflammation and delays in the healing process. The delays can lead to an injury never healing, forming excess scar tissue, or other complications.

Hemichannels are made of six Connexin43 proteins that come together to form a channel. Xequel’s alpha-connexin carboxyl-terminal 1 (aCT1) peptide mimics Connexin43 to regulate hemichannels and gap junctions. Our formulation accelerates the healing process, regardless of injury origin. Preclinical data for our novel aCT1 therapeutic supports a transformational response to healing.

Contact us for collaborations or partnership opportunities.